FibroBiologics Inc
FBLG
Company Profile
Business description
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Contact
455 East Medical Center Boulevard
Suite 300
HoustonTX77598
USAT: +1 281 671-5150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |